Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 418-427

  Lambrecht, Stijn ^a   Smith, Vanessa ^a   De Wilde, Katelijne ^a   Coudenys, Julie ^a   Decuman, Saskia ^a   Deforce, Dieter ^a   De Keyser, Filip ^a   Elewaut, Dirk ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; LONGITUDINAL STUDY; LUNG DEVELOPMENT; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG FUNCTION; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; BLEOMYCIN; CHEMOKINE CCL2; COHORT STUDIES; COMORBIDITY; DISEASE MODELS, ANIMAL; FIBROBLASTS; FOLLOW-UP STUDIES; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INTERLEUKIN-6; LONGITUDINAL STUDIES; LUNG; MICE; MICE, KNOCKOUT; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SKIN DISEASES; STROMAL CELLS;

EID: 84896277140     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38241     Document Type: Article

References (31)

1. Harris ML, Rosen A. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003;15: 778-84.
2. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360: 1989-2003.
3. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117: 557-67.
4. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18: 1028-40.
5. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF - superfamily. Proc Natl Acad Sci U S A 1997;94: 11514-9.
6. Bottner M, Laaff M, Schechinger B, Rappold G, Unsicker K, Suter-Crazzolara C. Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene 1999;237: 105-11.
7. Paralkar VM, Vail AL, Grasser WA, Brown TA, Xu H, Vukicevic S, et al. Cloning and characterization of a novel member of the transforming growth factor - /bone morphogenetic protein family. J Biol Chem 1998;273: 13760-7.
8. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 2010;224: 626-35.
9. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;115: 962-71.
10. Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009;30: 1057-65.
11. Taddei S, Virdis A. Growth differentiation factor-15 and cardiovascular dysfunction and disease: malefactor or innocent bystander? Eur Heart J 2010;31: 1168-71.
12. De Jager SC, Bermudez B, Bot I, Koenen RR, Bot M, Kavelaars A, et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Exp Med 2011;208: 217-25.
13. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28: 1573-6.
14. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60: 592-8.
15. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21:S42-6.
16. Vanthuyne M, Smith V, De Langhe E, Van Praet J, Arat S, Depresseux G, et al. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol 2012;39: 2127-33.
17. Smith V, Decuman S, Sulli A, Bonroy C, Piettte Y, Deschepper E, et al. Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? A pilot study. Ann Rheum Dis 2012;71: 1636-9.
18. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ. Characterization of growth-differentiation factor 15, a transforming growth factor - superfamily member induced following liver injury. Mol Cell Biol 2000;20: 3742-51.
19. Lambrecht S, Verbruggen G, Elewaut D, Deforce D. Differential expression of -B-crystallin and evidence of its role as a mediator of matrix gene expression in osteoarthritis. Arthritis Rheum 2009;60: 179-88.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 - C T method. Methods 2001;25: 402-8.
21. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:Research0034.
22. Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, McMahon FB, et al. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010;299:L442-52.
23. Shen ZJ, Braun RK, Hu J, Xie Q, Chu H, Love RB, et al. Pin1 protein regulates Smad protein signaling and pulmonary fibrosis. J Biol Chem 2012;287: 23294-305.
24. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23: 581-90.
25. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22: 1281-5.
26. Takahashi F, Takahashi K, Okazaki T, Maeda K, Ienaga H, Maeda M, et al. Role of osteopontin in the pathogenesis of bleomycininduced pulmonary fibrosis. Am J Respir Cell Mol Biol 2001;24: 264-71.
27. Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. Mod Rheumatol 2012;22: 668-75.
28. Meadows CA, Risbano MG, Zhang L, Geraci MW, Tuder RM, Collier DH, et al. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. Chest 2011;139: 994-1002.
29. Zhang K, Gharaee-Kermani M, Jones ML, Warren JS, Phan SH. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J Immunol 1994;153: 4733-41.
30. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999;104: 5-11.
31. Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012;180: 165-76.